Aravive (NASDAQ: ARAV) down 50% - well, that drug doesn’t work then

Aravive (NASDAQ: ARAV) stock is down 50% this morning. ARAV stock is down because of the announcement last night, after close. Effectively, the drug they’re testing doesn’t work. So, pretty much, that’s that. All that money, just gone.

Now this isn’t entirely and wholly true, there may be other cancers it works on and so on but the specific target they were testing for, nope, doesn’t work. From Aravive: “Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab). The Company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept.” It may be worth testing on renal cancers and so on but as far as ovarian is concerned, well, no. Doesn’t work.

Picture9

Aravive stock price from Google Finance

The lesson for us here as investors is that development stage pharma is risky. Well, OK, we probably already knew that. The entire point of doing all the testing is to find out what works. That means lots of money is going to be spent on things that don’t work as well. And all that spent on what doesn’t work is a bust, just lost money, as here at Aravive.

But this then tells us what our strategy should be in this sector. We can - and it’s most fun, even if grossly risky - just try to trade in and out as speculation. Not greatly known as a wealth enhancing activity but then nor are one armed bandits.

But if we think we’re going to invest in this field then we need to understand The field as a whole does make money. But the risks with any specific stock are the chance of a multibagger or a complete bust to zero. So, we should be thinking about having a portfolio in order to diversify risk. Of course, when investing we should always be thinking about diversification but this is even more true in this sector.